HepaLife Technologies, Inc., announces the development of two new derivative cell lines which can be used for the treatment of human liver failure. This stem cell lines will be used in Hepalife’s first -of-its-kind Bio artificial liver device which is currently under development phase.

Ongoing tests was done by the scientists, to check the functioning of the liver stem lines. The main focus was on PICM-19H and PICM-19B cell line. Tests proved that PICM-19H cells can favorably differentiate into hepatocytes and PICM-19B cell lines which differentiates exclusively into functional bile duct, can transform themselves into complete monolayers of cell in culture. These cells are basolaterally polarized cells exhibiting basal membrane fluid transport, having high GGT activity and have greatly reduced serum protein production.

HepaLife Technologies, Inc (OTCBB: HPLF) (FWB: HL1) (WKN: 500625) is a developer of cell-based medical technologies addressing prevalent human health concerns.They are developing the first-of-its-kind bio artificial liver device intended for the treatment of liver failure using the Company’s patented PICM-19 liver stem cell line.

This bio artificial Liver device consists of three basic components: (1) a plasma filter, separating the patient’s blood into blood plasma and blood cells; (2) the bio reactor, a unit filled with the patented PICM-19 liver stem cell line which biologically mimics the liver’s function; and (3), the HepaDrive(TM), a perfusion system for pumping the patient’s plasma through the bio reactor while controlling gas supply and temperature for best possible performance of the cells.

This development is supposed to be important breakthrough, particularly in an era of organ transplantation shortage.